Mirimus, Inc. Sorts Strategic Collaboration with Biogen to Create RNAi-Centered Therapeutics for Neurological Disease Indications

Tom Smith

&#13   &#13 &#13 NEW YORK, July 21, 2021 /PRNewswire/ — Mirimus, Inc., a pioneer in RNAi therapeutic design and style and CRISPR/Cas9 gene enhancing technological know-how implementation, today introduced a strategic collaboration with Biogen Inc. (NASDAQ: BIIB) targeted on the growth of RNAi-centered therapeutics focusing on a number of, […]

&#13

 

&#13

&#13

NEW YORK, July 21, 2021 /PRNewswire/ — Mirimus, Inc., a pioneer in RNAi therapeutic design and style and CRISPR/Cas9 gene enhancing technological know-how implementation, today introduced a strategic collaboration with Biogen Inc. (NASDAQ: BIIB) targeted on the growth of RNAi-centered therapeutics focusing on a number of, undisclosed neurological illness indications. Phrases of the collaboration between Mirimus and Biogen are undisclosed.

&#13
&#13

&#13
&#13

Mirimus was set up in 2010 with the intention of producing a scalable and price-successful pipeline for model generation and therapeutic progress by harnessing the energy of RNAi and CRISPR systems, like growth of animal models vital for preclinical evaluation of new therapeutics. Under the arrangement, Mirimus will utilize its knowledge to engineer RNAi-based therapeutics that will be assessed by Biogen to identify feasibility in opportunity neurological illness settings. If feasibility is proven, the businesses will have the solution to pursue pre-medical development of the asset(s).

&#13
&#13

“We are very pleased to announce our collaboration with Biogen, a very highly regarded pioneer in neuroscience,” stated Prem Premsrirut, M.D., Ph.D., Co-founder and CEO of Mirimus. “This collaboration marks an essential progress for Mirimus as we search for to prolong our experience in RNAi animal models to the enhancement of RNAi-based biotherapeutics. At our main, Mirimus’ strength is applying our scientific abilities to remedy advanced healthcare problems, no matter if that is pinpointing a new treatment method paradigm for a neurological condition, as in the scenario with Biogen, or establishing a game-shifting saliva-based mostly, pooled PCR screening platform to immediately and precisely isolate COVID-19 hotspots in advance of they can come to be outbreaks. The higher the obstacle, the a lot more excited we are at Mirimus.”

&#13
&#13

About Mirimus, Inc.
&#13
Mirimus, Inc. was established in 2010 with the purpose of developing a scalable and expense-helpful pipeline for design technology by harnessing the electric power of RNAi and CRISPR systems to produce animal models which are essential for preclinical evaluation of new therapeutics. Through slicing edge know-how, strong predictive equipment, and crucial partnerships, Mirimus is paving the path to develop safer and much more successful therapeutics by pin-pointing possible toxicities, validation, and sickness modeling. Since its founding, Mirimus has established alone as a leader in conducting large-quantity, complex and very powerful PCR testing. This exceptional skillset led Mirimus to produce SalivaClear, a COVID-19 tests system that combines saliva-based sampling, pooled screening and PCR diagnostics to improve the scalability, efficiency, cost-effectiveness and accuracy of COVID-19 testing. For extra facts, make sure you stop by www.mirimus.com and www.salivaclear.com.

&#13
&#13

Media Contacts:
&#13
Tiberend Strategic Advisors, Inc. 
&#13
Johanna Bennett & Ingrid Mezo
&#13
[email protected] / 1-212-375-2686
&#13
[email protected] / 1-646-604-5150

&#13
&#13

 

&#13
&#13

Cision Check out original content material to download multimedia:https://www.prnewswire.com/information-releases/mirimus-inc-forms-strategic-collaboration-with-biogen-to-establish-rnai-primarily based-therapeutics-for-neurological-sickness-indications-301338149.html

&#13
&#13

Source Mirimus, Inc.

&#13

&#13

 

&#13

Next Post

Comment on “Nonadjacent dependency processing in monkeys, apes, and humans”

Summary We remark on the technological interpretation of the analyze of Watson et al. and warning in opposition to their conclusion that the behavioral proof in their experiments details to nonhuman animals’ skill to study syntactic dependencies, because their outcomes are also regular with the mastering of phonological dependencies in […]

Subscribe US Now